Incretin Effect in Patients With Psoriasis and Controls

Completed

• Conditions: Psoriasis Vulgaris

• Registration Number: NCT06064084
• Lead Sponsor: University Hospital, Gentofte, Copenhagen

Brief Summary

To investigate the incretin effect and postprandial incretin responses in plasma in patients with psoriasis

Detailed Description

Not available

Study Timeline

• Study Start: 2011-09-11
• Primary Completion: 2015-09-11
• Study Completion: 2015-09-11
• Status Verified: 2023-09
• Study First Submitted: 2023-09-14
• Study First Submitted QC: 2023-09-28
• Last Update Submitted: 2023-09-28
• Study First Posted: 2023-10-03
• Last Update Posted: 2023-10-03

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 24

Inclusion Criteria

no diabetes BMI < 27 kg/m^2 normal Glucose tolerance test at screening normal fasting plasma glucose no islet auto antibodies no hormonel contraception informed consent psoriasis vulgaris (PASI>8) (case not controls)

Exclusion Criteria

other chronic inflammtory skin disease other chronic inflammatory disease pregnancy psychiatric illness

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Incretin effect measured with Beta-cell secretory response	0-180 minutes	Incretineffect (%) = 100 % × (Beta-cell Secretory Response (OGTT) - Beta-cell Secretory Response (IIGI)) / Beta-cell Secretory Response (OGTT)

Secondary Outcome Measures

Name	Time	Method
Concentration of Insulin	0-180 minutes	Evaluated as Area Under the Curve
Concentration of Glucagon-like peptide 1	0-180 minuntes	Evaluated as Area Under the Curve
Concentration of Glucagon	0-180 minutes	Evaluated as Area Under the Curve
Insulin sensitivity measures	0-180 minutes	Matsudas insulin sensitivity index: (10,000 / √glucose minute 0 x insulin minute 0) (mean glucose (OGTT) x mean insulin OGTT))
Concentration of Glucose-independent insulinotropic polypeptide	0-180 minutes	Evaluted as Area Under the Curve